Urinary Incontinence Therapeutics Market Set To Explode Opportunities, Future Scope 2025-2032 | Astellas Pharma, Pfizer

The Global Urinary Incontinence Therapeutics Market is estimated to be valued at USD 4.68 Bn in 2025 and is expected to reach USD 6.37 Bn by 2032.

BURLINGAME, CA, UNITED STATES, December 3, 2025 /EINPresswire.com/ -- The Global Urinary Incontinence Therapeutics Market¹ is estimated to be valued at USD 4.68 Bn in 2025 and is expected to reach USD 6.37 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032. This consistent growth is fueled by the rising prevalence of urinary incontinence, increasing awareness of available treatment options, and ongoing advancements in therapeutic interventions that enhance patient outcomes and overall quality of life.

Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/8767

Global Urinary Incontinence Therapeutics Market Key Takeaways

Global urinary incontinence therapeutics demand is likely to rise at a moderate CAGR of 4.5% from 2025 to 2032.

Muscarinic receptor antagonists (anticholinergics) remain the most widely used drug class for urinary incontinence treatment, accounting for 40.2% of the market in 2025.

Based on incontinence type, the urge/overactive bladder (OAB)/urge urinary incontinence (UUI) segment is slated to lead with a 30.2% share in 2025.

By route of administration, oral segment is projected to account for 30.4% of the global urinary incontinence therapeutics market share in 2025.

North America is expected to dominate the global urinary incontinence therapeutics industry with a share of 37.3% in 2025, owing to availability of various treatment options for urinary incontinence.

Asia Pacific, with an estimated share of 24.5% in 2025, is poised to become a hotbed for urinary incontinence therapeutics manufacturers. This is mostly due to rising demand for expanding patient pool and rising demand for urinary incontinence medications.

Rising Geriatric Population Spearheading Market Growth

Coherent Market Insights’ latest urinary incontinence therapeutics market analysis highlights key factors driving industry growth. Expanding geriatric population, rising prevalence of urological and chronic conditions, growing preference for non-surgical urinary incontinence solutions, and pharmaceutical innovations are some major urinary incontinence therapeutics market growth factors.

According to the World Health Organization (WHO), the global population aged 60 years and older is projected to reach 2.1 billion by 2050. This increases the number of people at risk for urinary incontinence (UI), leading to high demand for urinary incontinence therapeutics like anticholinergics, β₃-adrenergic receptor agonists, combination therapy, and neuromuscular blockers.

Studies estimate that hundreds of millions of adults globally are affected by urinary incontinence. Age-related weakening of bladder and pelvic-floor muscles, reduced bladder capacity, and neurological changes make UI more common in older adults. Thus, expanding geriatric population, coupled with rising prevalence of urinary incontinence, is expected to boost market growth.

Black Friday Limited-Time Offer: Enjoy Up to 40% Discount on This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/8767

High Costs and Alternative Treatments Limited Market Growth

The prospective urinary incontinence therapeutics market outlook remains optimistic, owing to rising incidence of urinary incontinence and growing need for effective pharmaceutical solutions for urinary incontinence. However, high treatment costs and increasing adoption of urinary incontinence devices and surgical procedures are expected to slow down urinary incontinence treatment market growth to some extent during the forecast period.

Many approved urinary incontinence therapies, including anticholinergics, beta-3 agonists, and hormone-based treatments, can be expensive. This reduces treatments accessibility, especially in low- and middle-income regions, which dampens overall urinary incontinence market demand. Moreover, the expanding urinary continence devices market also negatively impacts demand for drug-based therapies.

Some urinary incontinence patients opt for devices like urethral and vaginal slings, artificial urinary sphincters, implants, and neuromodulation systems. There is also growing interest in urinary incontinence surgery because of its high effectiveness and shorter recovery times. Adoption of these alternative treatments could slow down growth of the urinary incontinence therapeutics market in the coming years.

Rise in Urological Disorders and Chronic Conditions Creating Growth Prospects

Rising cases of urological disorders and chronic health conditions are expanding the patient pool for urinary incontinence (UI). This, in turn, creates lucrative growth prospects for the urinary incontinence therapy market. Conditions such as obesity and type 2 diabetes contributed to this trend. Excess body weight puts more pressure on the bladder and pelvic floor, and diabetes-related nerve and metabolic problems make it harder to control the bladder. As these chronic diseases become more common, more people experience urinary incontinence (UI), driving the demand for effective treatments.

Neurological conditions also boost urinary incontinence therapeutics market growth by contributing to more complex forms of UI that require long-term therapeutic management. Disorders such as spinal cord injuries, multiple sclerosis, Parkinson’s disease, and stroke can cause neurogenic bladder dysfunction, significantly elevating the risk of incontinence. This is driving demand for advanced and targeted UI medications, supporting sustained market expansion.

Emerging Urinary Incontinence Therapeutics Market Trends

Increasing urinary incontinence diagnostic rates are boosting market. Growing public health awareness, better patient education, and improved diagnostic practices are encouraging more people to seek treatment. This increases the addressable patient pool, thereby positively impacting sales of urinary incontinence therapeutics.

Combination therapies are gaining popularity for the treatment of urinary incontinence due to their higher efficacy. These combination therapies help address different mechanisms of bladder dysfunction and improve overall efficacy. Rising adoption of combination therapies is expected to boost urinary incontinence therapeutics market revenue in the coming years.

Novel drugs for urinary incontinence are making their way into the market. Leading manufacturers of urinary incontinence therapeutics are developing newer drug classes like beta-3 adrenergic receptor agonists, combination therapies, and neurotoxins to reduce the risk of side effects associated with traditional therapies. Emerging therapies for urinary incontinence offer better efficacy and tolerability as well as expand treatment options.

Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/8767

Analyst’s View

“The global urinary incontinence therapeutics market is set for steady growth, owing to increasing prevalence of urinary disorders, rising geriatric population, growing awareness of treatment options, and advancements in minimally invasive therapies and pharmaceutical interventions. Companies developing innovative, safe, and patient-centric solutions are well-positioned to capitalize on emerging opportunities,” said a senior CMI analyst.

Competitor Insights

Key companies listed in the urinary incontinence therapeutics market report include:

Pfizer
Astellas Pharma
AbbVie
Eli Lilly
Allergan
Teva Pharmaceutical
Merck
Janssen
Endo Pharmaceuticals
Mylan
Reddy’s Laboratories
Sumitomo Pharma
Takeda
GlaxoSmithKline
Sanofi

Key Developments

In July 2025, Eisai Co., Ltd. announced the launch of Beova Tablets in Thailand. This medication Beova, (generic vibegron), is indicated for overactive bladder treatment.

In December 2024, the U.S. FDA approved GEMTESA (vibegron) for use in men with overactive bladder symptoms who are also receiving pharmacologic therapy for Benign Prostatic Hyperplasia (BPH). This includes symptoms such as urge urinary incontinence, urgency, and urinary frequency.

About Us:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Raj Shah
Coherent Market Insights Pvt. Ltd.
+1 252-477-1362
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
X

¹ https://www.coherentmarketinsights.com/insight/request-sample/8767